{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-239304","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2021-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.761207+00:00","generated_at":"2026-06-29T20:53:59.263670+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Design Therapeutics VP Finance Resigns; Controller Appointed Interim Principal Accounting Officer","bullets":["Justin Thacker resigned as VP Finance and principal accounting officer effective August 13, 2021.","Dawn Giangiulio, Controller since April 2020, appointed interim principal accounting officer effective August 13, 2021.","Giangiulio also serves as Controller of ARS Pharmaceuticals on a part-time basis, resigning September 3, 2021.","Previously, Giangiulio was Senior Manager R&D Finance at Teva Pharmaceutical Industries from 2015 to 2020.","Giangiulio is a licensed CPA and began her career at PricewaterhouseCoopers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-239304","json":"https://secwatch.observer/filing/0001193125-21-239304.json","markdown":"https://secwatch.observer/filing/0001193125-21-239304.md","text":"https://secwatch.observer/filing/0001193125-21-239304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/d203283d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:53:59.263670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"012580959b","claim":"Justin Thacker resigned as VP, Finance at Design Therapeutics, Inc..","evidence_excerpt":"On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"VP, Finance"}],"fact_type":"executive_change"},{"claim_id":"9aba11ac28","claim":"Dawn Giangiulio was appointed as interim principal accounting officer at Design Therapeutics, Inc..","evidence_excerpt":"Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal accounting officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}